Evidence map›Paper›PMID 34704620›Full record

ArticleJournal of medical virology2022

Evaluation of antibody response after COVID-19 vaccination of healthcare workers.

Elif B Uysal, Sibel Gümüş, Bayhan Bektöre, Hale Bozkurt, Ayşegül Gözalan

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medical virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 80 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Observational
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Elif B UysalDepartment of Medical Microbiology, Alanya Alaaddin Keykubat University, School of Medicine, Alanya, Antalya, Turkey.ORCID 0000-0001-9481-5304
Sibel GümüşDepartment of Medical Microbiology, Alanya Alaaddin Keykubat University, School of Medicine, Alanya, Antalya, Turkey.
Bayhan BektöreAlanya Alaaddin Keykubat University, Education and Research Hospital, Alanya, Antalya, Turkey.
Hale BozkurtAlanya Alaaddin Keykubat University, Education and Research Hospital, Alanya, Antalya, Turkey.
Ayşegül GözalanDepartment of Medical Microbiology, Alanya Alaaddin Keykubat University, School of Medicine, Alanya, Antalya, Turkey.
Alanya University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The common goal of all vaccines developed against COVID-19, although they have been designed with different methods, is to develop an effective immunity and antibody response against SARS-CoV-2. However, the postvaccination immune response and antibody levels differ between individuals. This study examined the relationship between postvaccine seropositivity rates, age, gender, smoking, and body mass index (BMI), and antibody titers. A total of 314 healthcare workers (HCW) who were not previously infected with COVID-19 and who had received two doses of CoronaVac inactivated vaccine participated in the study. Seropositivity against the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein was measured from the participants 4 weeks after the second dose of vaccine using the electrochemiluminescence (ECLIA) method. In addition, the antibody developed against the nucleocapsid protein (NCP) was evaluated and compared using Elecsys Anti-SARS-CoV-2 kit. One hundred and eighty-one of the participants were female (57.6%) with a median age of 39 (interquartile range [IQR], 10) and 133 (42.4%) were male with a median age of 41 (IQR, 11). 99.6% of the volunteers developed seropositivity 4 weeks after the second dose of vaccine. It was also observed that the rate of RBD protein antibody titer was >250 U/ml in smokers, which is quite low compared to nonsmokers (p = 0.032), and that high RBD antibody titers were proportionally lower in obese participants, according to BMI values, compared to those with normal BMI (49.5% and 9.9%). It was observed that seropositivity developed in almost all participants after the CoronaVac vaccine. However, it was determined that the antibody titer measured varied depending on factors such as smoking, BMI, and duration.

Indexed as

COVID-19VaccinesAntibodies, ViralAntibody FormationCOVID-19 VaccinesFemaleHealth PersonnelHumansMaleSARS-CoV-2Spike Glycoprotein, CoronavirusVaccinationAntibodies, ViralCOVID-19 VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2VaccinesCoronaVachealthcare workersreceptor binding domainseropositivityspike protein

Identifiers

PMID34704620
PMCPMC8661654
OpenAlexW3208463258

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.